Sanders Morris Harris LLC Purchases 56,500 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Sanders Morris Harris LLC grew its holdings in Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) by 165.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90,600 shares of the company's stock after purchasing an additional 56,500 shares during the quarter. Sanders Morris Harris LLC owned about 0.27% of Sera Prognostics worth $725,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in Sera Prognostics by 7,357.8% in the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company's stock valued at $6,902,000 after buying an additional 873,002 shares during the period. Bank of New York Mellon Corp boosted its holdings in Sera Prognostics by 100.2% during the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company's stock worth $892,000 after purchasing an additional 75,441 shares during the last quarter. Geode Capital Management LLC grew its position in Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company's stock worth $4,578,000 after purchasing an additional 47,969 shares in the last quarter. State Street Corp grew its position in Sera Prognostics by 8.8% in the 3rd quarter. State Street Corp now owns 425,093 shares of the company's stock worth $3,316,000 after purchasing an additional 34,479 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in Sera Prognostics in the 2nd quarter valued at about $190,000. Institutional investors own 54.64% of the company's stock.

Insider Buying and Selling

In related news, insider Robert Gardner Harrison sold 14,209 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $7.39, for a total transaction of $105,004.51. Following the sale, the insider now owns 116,837 shares of the company's stock, valued at approximately $863,425.43. This represents a 10.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Paul Kearney sold 4,078 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $29,850.96. Following the sale, the insider now owns 176,889 shares in the company, valued at approximately $1,294,827.48. This represents a 2.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 93,215 shares of company stock valued at $666,835. 15.80% of the stock is owned by insiders.

Sera Prognostics Price Performance

Shares of NASDAQ SERA traded down $0.01 during midday trading on Thursday, reaching $6.60. The company's stock had a trading volume of 86,681 shares, compared to its average volume of 130,378. The stock has a market capitalization of $222.88 million, a P/E ratio of -6.67 and a beta of 0.86. The firm has a 50 day moving average price of $7.40 and a 200-day moving average price of $7.31. Sera Prognostics, Inc. has a 12-month low of $4.98 and a 12-month high of $12.35.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. On average, equities analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.